Cipla receives FDA approval for generic version of Valeant antidepressant
pharmafile | August 30, 2016 | News story | Manufacturing and Production, Sales and Marketing | Cipla, FDA, Valeant, Wellbutrin
Indian multinational pharma and biotech company Cipla has announced that its US arm InvaGen Pharmaceuticals has received approval from the FDA to market its generic bupropion hydrochloride extended release tablets for the treatment of major depressive disorder.
The firm’s product is a generic version of Valeant’s Wellbutrin XL tablets, available in 150mg and 200 mg. Valeant’s drug generated sales of approximately $792 million for the 12 month period ending June 2016.
The product is available for shipping immediately. Cipla’s shares have risen 0.76% to Rs 571.50 apiece on the BSE at the time of this writing.
Matt Fellows
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …





